DSIP: research

An experimental sleep peptide with small, mixed human studies and no FDA-approved dose.

Also called: Delta sleep-inducing peptide, Delta-sleep-inducing peptide, Emideltide.

Sleep peptides · Experimental nine-amino-acid peptide with uncertain sleep-signaling targets.

51 primary human research reports are listed, including biomarkers and overlapping series. Sleep trials are small and mixed; no human subcutaneous trial was found.

Studies

Healthy volunteers: morning infusion. crossover-rct, n=6, Six healthy adults, four men and two women.. Median sleep time during the next 130 minutes was 59% greater with DSIP than placebo. (source)
Early insomnia letter. rct, People with insomnia; sample size unavailable in retrieved letter.. No arm-level results were available in the retrieved record. (source)
Six adults with insomnia. crossover-rct, n=6, Six middle-aged adults with chronic insomnia.. Longer, less interrupted sleep was reported; benefit began in hour 2 and lasted up to 6 hours. (source)
Five early human experiments. case-series, Healthy volunteers and adults with insomnia in five small experiments.. Four evening doses reportedly normalized disturbed sleep; daytime tests suggested greater alertness. (source)
Insomnia after brain-stem injury. case-report, n=1, One person with severe insomnia after brain-stem lesions.. Baseline sleep was under 4 hours; DSIP improved sleep reversibly, without normalizing REM latency. (source)
Alcohol and opioid withdrawal pilot. open-label, n=67, 67 patients: 28 with alcohol withdrawal and 39 with opioid withdrawal.. 49 were evaluable; 48 improved: 22 alcohol patients and 26 of 27 opioid patients. (source)
Withdrawal: 107 inpatients. open-label, n=107, 47 alcohol-withdrawal and 60 opioid-withdrawal inpatients.. Marked improvement or disappearance of signs: 97% opioid and 87% alcohol patients; no placebo group. (source)
Narcolepsy: one patient. case-report, n=1, A 35-year-old man with a 10-year history of narcolepsy.. FDA reports six attacks at baseline versus three during either dosing week. (source)
Ten-injection insomnia series. open-label, n=7, Seven people with severe insomnia.. Reported in 6/7 people during 3-7 months of follow-up; no control group. (source)
Chronic pain pilot. open-label, n=7, Seven people with migraine, vascular headache, tinnitus or psychogenic pain.. 6/7 had lower pain ratings; associated depressive symptoms also improved. No placebo group. (source)
Middle-aged and older insomnia. single-arm, n=18, 18 adults with chronic insomnia, nine aged 29-59 and nine aged 60-83.. The authors reported normal sleep patterns at the end of follow-up; no parallel placebo arm. (source)
Sleep and daytime function. single-arm, n=14, 14 middle-aged adults with chronic insomnia.. Mean 313 minutes at baseline, 363.1 after the first dose and 385 after the last; no parallel placebo arm. (source)
Four-night crossover insomnia study. crossover-rct, n=6, Six people with severe chronic insomnia.. No significant change versus baseline or placebo for awakenings, sleep latency or waking time. (source)
Delayed sleep phase case. case-report, n=1, A 47-year-old woman with delayed sleep phase and low-dose benzodiazepine dependence.. Main sleep phase moved five hours earlier; flunitrazepam was stopped under close monitoring. (source)
ACTH crossover experiment. crossover-rct, n=11, 11 healthy men aged 25-39.. ACTH immunoreactivity fell for at least three hours versus saline; blood and urine cortisol did not change. (source)
Three-dose insomnia trial. rct, n=16, 16 adults with chronic insomnia.. Small gains in sleep efficiency and sleep latency versus placebo; subjective sleep quality did not improve. (source)
Growth hormone and prolactin. cohort, n=8, Eight healthy females aged 17-36; five in stimulation tests and three in overnight tests.. DSIP changed neither spontaneous nor arginine-induced growth hormone or prolactin secretion. (source)
Vasopressin and ACTH tests. crossover-rct, n=15, Eight healthy men plus seven additional men tested with a longer lead time.. DSIP lowered ACTH but did not alter basal or stimulated vasopressin responses. (source)
CRH and meal hormone tests. cohort, Healthy young men: five in each CRH condition and ten in a separate meal experiment.. Hormone responses were almost identical with DSIP and placebo after CRH and after a meal. (source)
Earlier opioid detoxification letter. case-report, Opioid detoxification case report; number of patients unavailable.. No arm-level results were available in the retrieved record. (source)
Seven-person opioid trial. open-label, n=7, Seven people with opioid dependence.. Mean SOWS-1 fell from 34.4 before the first injection to 17.8 afterward; post-dose timing unspecified. (source)
Nasal DSIP and P300. single-arm, Human intranasal experiment; full population details unavailable in retrieved letter.. The paper title reports increased P300, a brain response used in attention tasks; sleep benefit was not established. (source)
Older adults with diabetes. open-label, n=11, 11 older adults with diabetes; mean age 66.3 years.. Sleep, mood and post-meal glucose improved in before-after comparisons; no placebo group. (source)
Anesthesia depth and heart rate. rct, n=24, 24 women, ASA class I or II, undergoing surgery.. At 25 nmol/kg, DSIP increased BIS and reduced delta activity and burst suppression, suggesting lighter anesthesia. (source)
Retinal recovery and stimulation. cohort, People with diabetes and retinopathy, compared with controls.. Mean 137.2 ± 11.3 s with retinopathy; 95.1 ± 6.8 s with DSIP, 110.3 ± 12.7 s with stimulation, 82.5 ± 6.5 s combined. (source)
Nasal DSIP in retinal disease. cohort, n=45, 15 healthy volunteers and 30 adults with insulin-dependent diabetes, 15 with retinopathy.. Retinopathy: 137.2 ± 11.3 s before and 95.1 ± 6.8 s after treatment; healthy controls 73.5 ± 3.3 s. (source)
DSIP-like signals in breast milk. cohort, n=2, Two lactating women.. Milk signals fell from about 30 ng/mL in colostrum to about 10 ng/mL; no drug was administered. (source)
Blood and spinal-fluid signals. cohort, People with paired blood and spinal-fluid samples.. DSIP-like concentrations in blood and spinal fluid were correlated; no DSIP treatment was tested. (source)
Spinal-fluid signals in mental illness. cohort, People with schizophrenia or major depression and healthy volunteers.. Both patient groups had lower spinal-fluid DSIP-like concentrations than healthy controls. (source)
CRH challenge in depression. cohort, n=24, 12 people with major depression and 12 matched controls.. After 100 mcg CRH IV, DSIP-like signals rose slightly in controls and fell in depression; no DSIP was given. (source)
Lithium and DSIP-like signals. cohort, People with affective illness receiving lithium.. The title reports higher spinal-fluid DSIP with lithium; no abstract or numeric results were available. (source)
DSIP-like signals in brain disorders. cohort, People with dementia, Parkinson disease, vascular disease or hydrocephalus and controls.. DSIP-like signals rose with age in controls and were lower in several disease groups. (source)
DSIP-like signals and slow-wave sleep. cohort, n=15, 15 medication-free men with schizophrenia.. Spinal-fluid DSIP-like signals correlated with early-night slow-wave sleep; DSIP was not administered. (source)
Spinal-fluid signals after suicide attempts. cohort, n=44, 44 people after suicide attempts.. Participants with major depression had lower DSIP-like signals than other patient groups. (source)
Infant plasma signals. cohort, n=117, 28 preterm, 26 high-apnea, 37 healthy term infants and 26 siblings of SIDS victims.. Median DSIP was 1,885 pmol/L in healthy term infants, 1,595 in preterm and 1,542 in the high-apnea group. (source)
DSIP-like signals during dialysis. cohort, n=32, 22 stable hemodialysis patients and ten healthy controls.. Blood DSIP-like concentrations were higher during chronic kidney failure; this was not a drug-clearance test. (source)
Erythropoietin and DSIP-like signals. cohort, n=7, Seven stable hemodialysis patients during erythropoietin therapy.. DSIP-like concentrations did not change significantly over 28 weeks of erythropoietin treatment. (source)
Low blood sugar challenge. cohort, n=20, Ten people with type 1 diabetes and ten healthy people.. At induced glucose 2.0 mmol/L, mean DSIP did not change; injected DSIP was not tested. (source)
DSIP-like signals in Cushing syndrome. cohort, Three investigations in Cushing syndrome and healthy controls; cohort overlap unclear.. 08:00 DSIP-like signals: 797 ± 57 pmol/L in 65 patients versus 1,062 ± 99 in 49 controls, mean ± SEM. (source)
Day-night DSIP-like rhythm. cohort, n=12, 12 healthy volunteers with blood sampling and sleep recordings.. Levels peaked at 15:00 and were lowest at 01:00; they did not rise before slow-wave sleep. (source)
DSIP-like signals at sleep onset. cohort, n=7, Seven healthy men during normal sleep, sleep deprivation and recovery sleep.. DSIP-like signals fell at both evening and morning sleep onset, without a specific sleep-stage pattern. (source)
Signals in apnea and narcolepsy. cohort, Nine sleep-apnea, ten narcolepsy and 11 control participants; second comparison: eight apnea and 11 controls.. No significant plasma DSIP-like differences between groups; single measurements were not useful disease markers. (source)
Activity versus bed rest. cohort, n=5, Five healthy men sampled during usual activity and 34 hours of bed rest.. DSIP and phosphorylated DSIP showed no or minimal changes between activity and rest conditions. (source)
Signals in two forms of dementia. cohort, 39 Alzheimer-type and 41 frontotemporal dementia patients, plus controls.. Spinal-fluid DSIP was lower in Alzheimer-type disease but not frontotemporal dementia versus controls. (source)
Alzheimer and vascular dementia. cohort, People with Alzheimer or vascular dementia and healthy older controls.. DSIP was slightly higher in Alzheimer disease but not vascular dementia; biomarker findings conflicted with other studies. (source)
Hydrocephalus and shunt surgery. cohort, 12 Alzheimer, 11 multi-infarct dementia and ten hydrocephalus patients, plus healthy controls.. DSIP was low in hydrocephalus and rose three months after shunt surgery; no DSIP drug was given. (source)
Earlier dementia signal report. cohort, People with Alzheimer-type or frontotemporal dementia.. DSIP-like signals were lower in Alzheimer disease and slightly higher in frontotemporal dementia. (source)
Blood signals after suicide attempts. cohort, 34 people after suicide attempts and matched healthy controls.. Plasma DSIP-like signals were higher in participants with major depression, p<0.005. (source)
Temperament and peptide signals. cohort, 38 suicidal patients and matched controls.. DSIP correlated with impulsiveness in controls; associations did not establish a treatment effect. (source)
Signals after brain hemorrhage. cohort, n=17, 17 people with good neurological recovery after aneurysmal brain hemorrhage.. Nine had cognitive impairment; higher spinal-fluid DSIP correlated with poorer cognition, p=0.045. (source)
Orexin and DSIP-like signals. cohort, n=66, 66 people after suicide attempts with mood or adjustment disorders.. Spinal-fluid orexin correlated with DSIP-like signals; this was not a DSIP treatment study. (source)
Early human blood assay. in-vitro, Human plasma studied in the laboratory.. Assay detected large and small DSIP-like fractions, with higher values at 16:00 than 08:00. (source)
Free and bound DSIP-like material. in-vitro, Human blood, spinal fluid and urine, plus animal blood.. Chromatography found DSIP-like peaks matching synthetic DSIP; this alone does not establish a natural sleep hormone. (source)
Infant brain-tissue survey. in-vitro, Postmortem infant and adult hypothalamus, including SIDS cases.. Immunochemical studies mapped DSIP-like signals; postmortem and age effects limit interpretation. (source)
Infant brain mapping pilot. in-vitro, Seven normal infant hypothalamus specimens.. DSIP-like staining varied by region and age; no peptide was administered. (source)
Newborn and infant brain mapping. in-vitro, Normal human hypothalamus in the first year of life.. DSIP-like cell bodies and fibers were found in several hypothalamic regions. (source)
Aged human brain mapping. in-vitro, Aged human brain specimens.. The study mapped DSIP-like and reproductive-hormone-related staining; no treatment outcome was tested. (source)
Human pituitary mapping. in-vitro, Human pituitary specimens.. DSIP-like staining overlapped corticotropin-related cells; this does not show a response to injected DSIP. (source)
Peptide signals in schizophrenia tissue. in-vitro, Postmortem temporal cortex and hypothalamus from people with schizophrenia.. Several peptide concentrations were studied; DSIP-specific treatment effects were not tested. (source)
Signals in gut tumor cells. in-vitro, Human midgut carcinoid tumor samples and cell preparations.. DSIP-like and serotonin signals coexisted in tumor cells; no evidence that administered DSIP causes tumors. (source)
Signals in gut hormone cells. in-vitro, Human, pig and rat gut specimens.. Human gut had abundant DSIP-like material; chromatography suggested a peptide fragment, not necessarily intact DSIP. (source)
Signals in adrenal tumor cultures. in-vitro, Nine human pheochromocytoma tumors and cultured cells.. 25-75% of primary tumor cells stained for DSIP-like material; cultures released several reactive fractions. (source)
Signals in a lung-cancer cell strain. in-vitro, A human small-cell lung-cancer strain.. Antibody staining detected DSIP-like material; this is not evidence of tumor growth from DSIP dosing. (source)
Breakdown in blood samples. in-vitro, Human and rat blood incubated with DSIP and two analogues.. DSIP disappeared mainly through breakdown; modified analogues lasted longer and formed complexes. (source)
Intestinal-cell transport. in-vitro, Cultured human intestinal Caco-2 cell layers.. 8.2 ± 1.1% on the apical side versus 70.6 ± 3.0% on the basolateral side. (source)
Animal sleep and withdrawal. animal, Rabbits, cats and morphine-dependent mice.. Some sleep and withdrawal measures improved; many responses followed a bell-shaped dose curve. (source)
Mouse lifespan experiment. animal, n=108, Female Swiss-derived SHR mice, 54 per group.. Mean lifespan did not change; maximum lifespan rose 24.1% and lifespan of the last 10% of survivors rose 17.1%. (source)
Early insomnia overview. review, Published DSIP literature.. Summarizes earlier single and repeated injections; overlap prevents counting this as a new cohort. (source)
Sleep-disturbance overview. review, Published DSIP literature.. Summarizes blinded insomnia studies and a narcolepsy case; no independently counted new cohort. (source)
Pharmacology review. review, Published DSIP literature.. Describes mixed human sleep results, rapid breakdown and a theoretical captopril interaction. (source)
Mechanism remains unresolved. review, Published DSIP literature.. No specific gene, precursor protein or receptor had been established; natural sleep-factor status was questioned. (source)

DSIP dosage

Typical reported dose: 500 mcg at bedtime

Morning infusion: 25 nmol/kg: 25 nmol/kg IV over 20 minutes one infusion on the active crossover day, into a vein. Studied in a trial. Studied in: Six healthy adults, four men and two women. (source)
Bedtime crossover: 25 nmol/kg: 25 nmol/kg IV over 4 minutes on active nights in P-D-P or D-P-D sequence, into a vein. Studied in a trial. Studied in: Six middle-aged adults with chronic insomnia. (source)
Single evening infusion: 25 nmol/kg IV over 4 minutes single dose, into a vein. Studied in a trial. Studied in: Healthy volunteers and adults with insomnia in five small experiments. (source)
Four evening infusions: 25 nmol/kg IV over 4 minutes on four evenings once daily for four consecutive evenings, into a vein. Studied in a trial. Studied in: Healthy volunteers and adults with insomnia in five small experiments. (source)
Six morning infusions: 25 nmol/kg IV on six consecutive mornings once daily for six mornings, into a vein. Studied in a trial. Studied in: Healthy volunteers and adults with insomnia in five small experiments. (source)
Seven nights: 30 nmol/kg: 30 nmol/kg IV each night on laboratory nights 3-9 once nightly for seven consecutive nights, into a vein. Studied in a trial. Studied in: 14 middle-aged adults with chronic insomnia. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

DSIP side effects and risks

Reported side effects

Transient sweating, headache, nausea or vertigo: 9/107 had one or more minor events in the IV withdrawal series; counts for each symptom were not given., mild. Stop and seek assessment if symptoms persist or worsen. (source)
Low blood pressure: 2/107 in the IV withdrawal series; one worsened after another injection. Route specific community rates are unknown., serious. Fainting or severe dizziness needs urgent care. (source)
Repeated discomfort with sweating and nausea: 1/107 in the IV withdrawal series; episodes lasted about 15 minutes and were classified as serious by FDA., serious. Stop and get medical assessment. (source)
Faster heart rate: Observed during the 24 person anesthesia study; event counts and absolute change unavailable in the abstract., moderate. Report palpitations; chest pain or fainting needs urgent care. (source)
Worse insomnia or next-day grogginess: Community reports; no reliable denominator or proven causal link., moderate. Stop if sleep or daytime alertness worsens; avoid driving while impaired. (source)
Low mood or loss of motivation: One detailed user report at 100 mcg five nights weekly; no clinical incidence estimate., moderate. Stop and discuss mood changes with a clinician. (source)
Allergic or immune reaction: FDA warns about potential immune reactions to peptide impurities or aggregates; DSIP incidence is unknown., serious. Breathing trouble, throat swelling or collapse needs emergency help. (source)

Stop and get help if

Throat or tongue swelling, trouble breathing, or collapse: Stop exposure and call emergency services now.
Fainting, severe dizziness or chest discomfort after dosing: Stop and get urgent medical assessment.
Fever, spreading injection-site redness or feeling acutely unwell: Stop injections and get urgent assessment for infection or contamination.
Very low blood sugar with confusion or inability to swallow: Use the prescribed emergency plan and call emergency services.

Who should avoid it

pregnant: No adequate pregnancy or fetal-safety data. Avoid exposure during pregnancy.
breastfeeding: Safety after taking DSIP while breastfeeding is unknown. Native DSIP-like material in milk does not establish drug safety.
tryingToConceive: Reproductive safety has not been established. Avoid exposure while trying to conceive.
under18: No established pediatric dose or adequate child-safety program. The reference uses an adult-only screen.
other: A previous serious allergic reaction should stop re-exposure to that substance.
other: Low blood pressure occurred with IV dosing, including worsening after repeat exposure.
heartCondition: An anesthesia study found faster heart rate and altered heart-rate variability. Safety in heart disease is unknown.
kidneyDisease: No validated dose adjustment or safety data for kidney disease. Elevated native DSIP signals during dialysis do not define drug clearance.
liverDisease: Drug exposure, safety and dose adjustment in liver disease are unknown.
psychiatricCondition: Users have reported low mood, low motivation or worse sleep. Controlled psychiatric safety data are lacking.
sleepApnea: DSIP has not been shown to improve sleep apnea. Breathing pauses and daytime sleepiness need assessment.
surgeryPlanned: Tell the anesthesia team about DSIP. One human trial found lighter anesthesia and faster heart rate.
diabetes: A small uncontrolled combination-product study reported lower post-meal glucose. Its effect with diabetes medicines is unknown.
testedAthlete: DSIP is not named on the 2026 list. S0 coverage depends on therapeutic approval status; obtain an anti-doping ruling.

Interactions

Captopril and other ACE inhibitors: A review raises a theoretical peptidase interaction with captopril. Clinical effects and extension to other ACE inhibitors are untested.
Anesthetic drugs: DSIP altered anesthesia depth and heart-rate signals with propofol and isoflurane. Other anesthetics were not established as safe combinations.
Alcohol, opioids and sleep medicines: DSIP combination effects are poorly studied and may affect alertness unpredictably. It is not an established substitute for supervised withdrawal.
Insulin and sulfonylureas: A small uncontrolled study reported lower post-meal glucose. A DSIP interaction is unproven; avoid self-adjusting diabetes medicines.

Product quality risks

Health Canada’s DSIP-inclusive warning describes wrong amounts, unknown ingredients, microbes, endotoxins and particles in unauthorized peptides.
FDA found inconsistent salt and identity descriptions in DSIP nomination documents and warned about peptide impurities and aggregates.
No peer-reviewed survey quantifying purity or contamination of online DSIP vials was found. There is no reliable DSIP-specific failure rate.

How DSIP works

DSIP was named after slow brain waves seen in early animal work. Its natural role and specific receptor remain uncertain. Human results do not support a simple sleeping-pill effect.

Sleep and body-clock pathways: Proposed effects on sleep timing and slow waves are inconsistent across studies.
Stress-hormone pathways: Some human tests lowered ACTH; others found no change in ACTH or cortisol.
Endogenous opioid signaling: Animal experiments suggest indirect opioid-system effects; a direct opioid receptor action is unproven.

Half-life: A 2001 review cites 7-8 minutes in human plasma. This does not establish half-life after an injection under the skin.

Gaps: No published human subcutaneous dose, absorption, titration or long-term safety study was found. No controlled nasal sleep trial was found. Retinal and P300 studies cannot validate a nasal sleep regimen. Early sleep and withdrawal papers may report overlapping participants; the number of independent cohorts is unknown. Several old letters lack accessible full text. Missing dose, sample-size and adverse-event details were not reconstructed. The 1986 primary abstract says six injections, while FDA’s summary says five evenings; exact spacing remains unresolved. No established clinician-published sleep dose outside the research reports was found. Fertility, pregnancy, breastfeeding, pediatric, organ-disease and interaction safety are inadequately studied. The native molecule, specific receptor and relation of DSIP-like assay signals to injected DSIP remain uncertain. No DSIP-specific online-product failure rate, validated home-mixing shelf life or nasal delivery calibration was found. Current Russian product authorization and its effect on WADA S0 coverage remain unresolved. No relevant ClinicalTrials.gov record or Cochrane DSIP treatment review was found in the searches. UK authorization and Australian class-based scheduling remain unconfirmed.

Related to DSIP

Ipamorelin: An experimental peptide that triggers growth hormone release.
Selank: A Russian nasal anxiety peptide with uncertain long-term benefit and safety.
CJC-1295 without DAC: A peptide intended to trigger growth hormone release, with no human dosing study found.
Pinealon: A peptide with unproven brain benefits and no established injection dose.

DSIP: the short version

Sources

503B Bulk Drug Substances List, FDA · FDA · 2026
Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
Download medicine data, European Medicines Agency · European Medicines Agency · 2026
FDA Briefing Document: Emideltide-Related Bulk Drug Substances (Emideltide (free base) and Emideltide acetate), U.S. Food and Drug Administration · 2026
MHRA Products | Home, MHRA · MHRA · 2026
Sepsis, NHS · 2026
The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
Anaphylaxis, NHS · NHS · 2023
Low blood sugar (hypoglycaemia), NHS · 2023
[Using deltalicin for the treatment of patients with diabetic retinopathy]., Kresiun NV et al. · Eksperimental'naia i klinicheskaia farmakologiia · 2014
The influence of deltalycyn and transcranial cerebellar stimulation upon recovery of retina after photo stress in patients with diabetic retinopathy., Kresyun NV et al. · Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi · 2014

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.